BPC-157 Canada — Buy 5mg & 10mg Research Peptide

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). It is a fragment of a larger protein (BPC, about 40 kDa) that was isolated from gastric juice, and the fragment was first characterized in 1993 by Sikirić and colleagues^{[1, 2]}. Since then it has been studied almost entirely in rodent and cell-culture models of tissue injury, blood-vessel biology and the nitric oxide system^{[9, 11]}. It has no approved formulation for any use^[12]. The vials listed on this page are supplied as lyophilized powder for in-vitro and preclinical laboratory research only.

Key facts

• Sequence: GEPPPGKPADDAGLV (15 residues; a pentadecapeptide) — PubChem CID 9941957^[3]
• Molecular formula: C₆₂H₉₈N₁₆O₂₂ — PubChem and ChEMBL agree
• Molecular weight: 1419.5 g/mol (PubChem); 1419.56 (ChEMBL); reported as “M.W. 1419” in the primary literature^{[3, 10]}
• CAS number: 137525-51-0 · UNII: 8ED8NXK95P · ChEMBL: CHEMBL4297358
• Other names: Bepecin, PL-10, PLD-116, PL 14736 (the Pliva development codes used in inflammatory-bowel-disease trials)^[10]
• Origin: fragment of a gastric juice protein, described in 1993^[1]
• Research status: preclinical. No approved formulation, no validated dosing regimen and no completed Phase II trial as of a 2026 review^[12]; a 2025 systematic review found 35 preclinical studies and one retrospective clinical report, and no clinical safety data^[11]
• Formats on this site: 5mg and 10mg single-compound vials, plus BPC-157/TB-500 blends — all lyophilized powder, for laboratory research only.

Where does BPC-157 come from?

In 1993 Sikirić and co-workers reported the isolation of a gastric juice protein with a relative molecular mass of about 40,000, which they named BPC, and described a 15-amino-acid fragment — BPC 157 — that they considered essential for its activity. The same paper proposed the “stomach-stress-organoprotection” hypothesis: that the stomach, as a large neuroendocrine organ, mounts a protective counter-response to stress, and that BPC might be one of its mediators^[1]. A companion study the same year compared the synthetic fragment with bromocriptine, amantadine and somatostatin in rat models of liver injury (bile-duct plus hepatic-artery ligation, restraint stress, carbon tetrachloride)^[2]. Later papers describe the peptide as being formed constitutively in the gastric mucosa and as stable in human gastric juice^{[6, 12]} — the property behind the recurring phrase “stable gastric pentadecapeptide” in the literature.

In the early 2000s the compound was taken into clinical development for inflammatory bowel disease by the Croatian company Pliva under the codes PL-10, PLD-116 and PL 14736^{[3, 10]}. No approved product resulted; a 2026 biopharmaceutical review notes that available human data come from fewer than 30 subjects across three uncontrolled pilot studies^[12].

Chemical identity

What has been studied in the laboratory?

The published work is preclinical: rats, mice, chick embryos and cultured cells. The statements below describe what those studies reported in their models, not effects in people.

Tendon and connective-tissue models (rat)

In 2003 Staresinic and colleagues transected the right Achilles tendon of rats and gave BPC 157 intraperitoneally once daily, dissolved in saline with no carrier. Compared with saline controls, treated animals showed higher load to failure and Young’s modulus at biomechanical testing, higher Achilles functional index scores, and on microscopy more fibroblasts, reticulin and collagen with fewer granulocytes. In the same paper, the peptide had no effect on the growth of cultured tendocytes on its own but opposed the growth-inhibiting effect of 4-hydroxynonenal^[3].

Chang and colleagues (2011) cultured tendon explants and fibroblasts from rat Achilles tendon. BPC 157 accelerated the outgrowth of fibroblasts from explants, did not change proliferation in an MTT assay, increased cell survival under hydrogen-peroxide stress, and dose-dependently increased migration and spreading, with increased phosphorylation of FAK and paxillin^[4]. A 2014 follow-up from the same group used a cDNA microarray on rat tendon fibroblasts and found growth hormone receptor among the most up-regulated genes; the increase was dose- and time-dependent at both mRNA and protein level, and adding growth hormone to treated cells increased proliferation and activated JAK2^[5].

A 2026 rat study compared BPC-157, TB-500 and their combination after Achilles transection and repair (eight rats per group, four weeks). Both peptides were associated with improved histopathology scores; the biomechanical difference reached statistical significance only in the TB-500 group, and the combination gave no additional benefit. The authors describe the work as exploratory and call for dose-optimisation and longer studies^[13].

Blood vessels and the VEGFR2 pathway (chick embryo, rat, human cells in vitro)

Hsieh and colleagues (2017) reported that BPC 157 increased vessel density in the chick chorioallantoic membrane assay and in an endothelial tube-formation assay, and accelerated blood-flow recovery (laser Doppler) in a rat hind-limb ischaemia model. In cultured human vascular endothelial cells the peptide increased VEGFR2 mRNA and protein — but not VEGF-A — promoted VEGFR2 internalisation, and activated the VEGFR2–Akt–eNOS pathway; the endocytosis inhibitor dynasore blocked these effects^[8]. A 2014 review from the Zagreb group summarises the vascular literature and lists NO, VEGF and FAK among the pathways proposed^[7].

Nitric oxide system (rat)

A 2014 review examined the relationship between BPC 157 and the NO system in rat models: the peptide is reported to interact with both the NOS inhibitor L-NAME and the substrate L-arginine, in settings that include alcohol-induced gastric lesions, blood-pressure regulation, cardiovascular disturbance models and fistula healing. The authors state that how this might translate to clinical performance “remains to be determined”^[6].

Gastrointestinal and organ-protection models (rat)

The earliest work used rat models of gastric, hepatic and other organ lesions^{[1, 2]}. A 2006 review describes experiments in the fully distended rat stomach after absolute-alcohol instillation, in which BPC 157 was associated with preserved serosal blood-vessel presentation and reduced gastric, oesophageal and duodenal lesions compared with atropine, ranitidine and omeprazole^[10]. A 2021 review covers skin-wound models (incisional and excisional wounds, burns, alkali burns, diabetic ulcers) and fistula models in rats^[9].

Pharmacokinetics and safety data

Reviews from the originating group repeatedly note that an LD1 was not reached in animal toxicity testing^{[6, 9]}. A 2025 systematic review in orthopaedic sports medicine (36 included studies, 35 of them preclinical) reports a plasma half-life under 30 minutes, hepatic metabolism and renal clearance, and states that no clinical safety data were found^[11]. A 2026 biopharmaceutical review confirms the sub-30-minute half-life in a two-species preclinical ADME study, with intramuscular bioavailability of 14–51% depending on species, and contrasts this with biological effects reported to last hours to days — a disconnect the authors flag as unresolved^[12].

Study summary

What the evidence does not show

Almost all of the data above come from rats or cell culture. The one clinical report in the 2025 systematic review is a retrospective series of 12 patients, and that review found no clinical safety data^[11]. Human pharmacokinetics are described as “critically undercharacterized”, and no pharmaceutical-grade formulation has been validated^[12]. BPC-157 is not approved by Health Canada, the FDA or the EMA, and its use is prohibited in professional sport^[11]. Nothing on this page describes or implies an effect in humans, and no dosing or administration information is given here or anywhere on this site.

Batch documentation

Every batch is tested by an independent laboratory and the report is filed in the COA library under the batch number printed on the label; the site’s policy is HPLC for purity and mass spectrometry for identity, read separately (why). At the time of this review a report is posted for the BPC-157 5 mg batch on its product page — Janoshik test report #172065, analysis date 18 June 2026, measured content 5.42 mg, purity 99.582% (view) — and the library holds one for the BPC-157/TB-500 10 mg blend. A report specific to the 10 mg single-compound vial is not yet posted; that page says so rather than borrowing the 5 mg result.

Handling and storage in the laboratory

• Form: lyophilized (freeze-dried) powder in a sealed vial. The labelled amount is printed on the vial; the measured content of a batch is on its report.
• Storage of the sealed vial: −20 °C for long-term storage; the site states lyophilized material remains stable for up to 24 months at that temperature. For short periods keep it cool, dry and out of direct light, and avoid repeated temperature cycling.
• Reconstitution: in the published rodent studies the peptide was dissolved in saline with no carrier added^[3]. Laboratories commonly reconstitute lyophilized peptides with sterile or bacteriostatic water. Solutions are less stable than the dry powder; specific protocols are the responsibility of the qualified researcher and are not given on this site.
• Chemical stability: the literature reports the peptide as stable in human gastric juice^{[6, 12]} — a property of the molecule that is unusual for a peptide of this size and is one reason it has been studied.
• Half-life in circulation (preclinical): under 30 minutes in plasma^{[11, 12]}.

References

All references were retrieved from PubMed (NCBI) on 30 September 2026; identity data from PubChem and ChEMBL (EMBL-EBI) on the same date. Where two sources gave slightly different molecular weights, both are shown.

1. Sikirić P, Petek M, Rucman R et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of physiology, Paris 87(5):313-27. doi:10.1016/0928-4257(93)90038-u. PMID 8298609
2. Sikiric P, Seiwerth S, Grabarevic Z et al. (1993). Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life sciences 53(18):PL291-6. doi:10.1016/0024-3205(93)90589-u. PMID 7901724
3. Staresinic M, Sebecic B, Patrlj L et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 21(6):976-83. doi:10.1016/S0736-0266(03)00110-4. PMID 14554208
4. Chang CH, Tsai WC, Lin MS et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985) 110(3):774-80. doi:10.1152/japplphysiol.00945.2010. PMID 21030672
5. Chang CH, Tsai WC, Hsu YH et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (Basel, Switzerland) 19(11):19066-77. doi:10.3390/molecules191119066. PMID 25415472
6. Sikiric P, Seiwerth S, Rucman R et al. (2014). Stable gastric pentadecapeptide BPC 157-NO-system relation. Current pharmaceutical design 20(7):1126-35. doi:10.2174/13816128113190990411. PMID 23755725
7. Seiwerth S, Brcic L, Vuletic LB et al. (2014). BPC 157 and blood vessels. Current pharmaceutical design 20(7):1121-5. doi:10.2174/13816128113199990421. PMID 23782145
8. Hsieh MJ, Liu HT, Wang CN et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of molecular medicine (Berlin, Germany) 95(3):323-333. doi:10.1007/s00109-016-1488-y. PMID 27847966
9. Seiwerth S, Milavic M, Vukojevic J et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology 12:627533. doi:10.3389/fphar.2021.627533. PMID 34267654
10. Sikiric P, Seiwerth S, Brcic L et al. (2006). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology 14(5-6):214-21. doi:10.1007/s10787-006-1531-7. PMID 17186181
11. Vasireddi N, Hahamyan H, Salata MJ et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery 21(4):485-495. doi:10.1177/15563316251355551. PMID 40756949
12. Mateescu DM, Gavrilescu DM, Constantinescu FE et al. (2026). BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics 18(5). doi:10.3390/pharmaceutics18050625. PMID 42198317
13. Biçer O, Adanir O, Güleryüz Y et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery 37(3):822-837. doi:10.52312/jdrs.2026.2951. PMID 42542926